EVGN: יחס שווי שוק להכנסות Evogene Ltd.

Evogene Ltd. (EVGN) utilizes Big Data and the CPB system to accelerate the synthesis of pharmaceuticals and agrochemicals. The high productivity of its software core currently drives the development of the R&D pipeline in computational biology. Growth is supported by partner payments and the search for new therapeutic targets. The P/S multiple demonstrates the correlation between the share price and revenue, with the value maintained at 3.80.

Evogene Ltd. (EVGN) automates plant breeding via AI platforms, transforming biological design into a digital asset. The P/S ratio compares current market capitalization to annual sales volume, measuring the cost of every dollar of revenue. This calculation helps investors determine the extent to which the business is overvalued relative to its ability to generate income. Price-to-sales valuation trends allow for the timely identification of market imbalances and the risk of asset stagnation.